Document is current

Article History

Accepted: 10 September 2024

First Online: 18 October 2024

Competing interests

: K.N. has received personal fees from Pfizer, GSK and TESARO, Boehringer Ingelheim, travel grants from Conquer Cancer Foundation and research funding from Cancer Research UK. V.M. is employed by Northwest Permanente. B.A.M. receives funding from the Prostate Cancer Foundation (PCF), the American Society for Radiation Oncology (ASTRO), the Department of Defense, and the Sylvester Comprehensive Cancer Center. E.P. reports receiving consulting fees from Janssen and Merck Sharp & Dohme, financial support from Bayer, and non-financial support from Amgen and Astellas. D.E.S. reports personal fees from Janssen, Blue Earth, AstraZeneca and Boston Scientific outside the submitted work. P.L.N. reported receiving grants and personal fees from Bayer, Janssen and Astellas and personal fees from Boston Scientific, Dendreon, Ferring, COTA, Blue Earth Diagnostics, Myovant Sciences and Augmenix outside the submitted work. R.H. reports grants/research support from AstraZeneca, National Institute for Health Research (NIHR) and Asthma UK (AUKCAR); honoraria/consultation fees from AbbVie, Amgen, Astellas, AstraZeneca, Biogen, Erasmus, Idec, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp Dohme, Novartis, Pfizer, Roche, Shire Pharmaceuticals and TEVA; and is a founder and shareholder of a UCL Business company (Spoonful of Sugar) providing consultancy on supporting patients with medicine- and treatment-related behaviours to healthcare policymakers, providers and industry. Z.M. reports paid work for UCL Business Company Spoonful of Sugar. All other authors declare no competing interests.